MARKET NEWS

INCOG BioPharma Services Builds State-of-the-Art Facility With Promise to Deliver a Better Customer Experience
HUTCHMED Receives Breakthrough Therapy Designation in China for HMPL-523 for Treatment of Primary Immune Thrombocytopenia
Zai Lab Announces First Patient Treated in PANOVA-3 Phase 3 Pivotal Trial of Tumor Treating Fields in Pancreatic Cancer
Catalent Increases Specialized Packaging Capabilities at its Philadelphia Facility to Support Growing Biologic & Cell & Gene Therapy Markets
Definitive Agreement to Acquire Exelead Will Strengthen the CDMO Offering for mRNA of the Life Science Business of Merck KGaA, Darmstadt, Germany 
SK Inc., the Second Largest Conglomerate in South Korea, Has Invested $350 Million in the Center for Breakthrough Medicines 

  FEATURED EDITORIAL

  COMPANY PROFILE

Enteris BioPharma Inc., a wholly owned subsidiary of SWK Holdings Corp. (Nasdaq: SWKH), is a fully integrated development and manufacturing organization offering innovative oral drug delivery solutions. Since its founding in 2013, Enteris has adapted its oral drug delivery technology to advance multiple internal and client programs into the clinic. More recently, Enteris has completed a renovation of its 32,000 square-foot GMP facility, including HPAPI containment and handling, in Boonton, New Jersey, enabling long-term partnerships for challenging solid oral drug product development from preclinical through commercial cGMP manufacturing. Click her for more.

  EXCLUSIVE ONLINE CONTENT

 

Q-VANT Biosciences Launches to Solve the Pharmaceutical Industry Problem of Limited Quillaja Saponin-Based Adjuvants for Life-Saving Vaccines

Q-VANT Biosciences Launches to Solve the Pharmaceutical Industry Problem of Limited Quillaja Saponin-Based Adjuvants for Life-Saving Vaccines

Q-VANT Biosciences has launched as the first company to achieve a 100% sustainable way to meet the growing global vaccine market demand for Quillaja saponin-based adjuvants including QS-21. QS-21 is considered the “Gold Standard” adjuvant for enhancing immune….

COVAXIN (BBV152) Booster Shown to Neutralize Both Omicron & Delta Variants of SARS-CoV-2

COVAXIN (BBV152) Booster Shown to Neutralize Both Omicron & Delta Variants of SARS-CoV-2

Ocugen, Inc.and its partner, Bharat Biotech recently announced results from a study conducted at Emory University demonstrating that sera from subjects who received a booster dose of candidate vaccine….

atai Life Sciences Announces FDA IND Clearance for PCN-101 R-ketamine Program

atai Life Sciences Announces FDA IND Clearance for PCN-101 R-ketamine Program

atai Life Sciences N.V. recently announced the US FDA has given Investigational New Drug (IND) clearance to conduct a clinical DDI study of PCN-101 (R-ketamine). atai plans to initiate the….

Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct

Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct

Sana Biotechnology, Inc., IASO Biotherapeutics, and Innovent Biologics recently announced the companies entered into an agreement pursuant to which Sana obtained from IASO Bio and Innovent non-exclusive commercial rights to a clinically validated fully-human BCMA CAR construct for use in certain….

Malvern Panalytical Expands Pharmaceutical Drug Development Solutions Through Acquisition of Creoptix

Malvern Panalytical Expands Pharmaceutical Drug Development Solutions Through Acquisition of Creoptix

Malvern Panalytical recently announced its acquisition of Creoptix AG, a specialist bioanalysis sensor company. The acquisition forms a critical part of Malvern Panalytical’s strategy to….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

January 26 – Bioavailability
February 2 – Analytical Instrumentation